Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4919-4926, October 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, J.
Right arrow Articles by Sebti, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, J.
Right arrow Articles by Sebti, S. M.
[Cancer Research 59, 4919-4926, October 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I

Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine1

Jiazhi Sun, Michelle A. Blaskovich, David Knowles, Yimin Qian, Junko Ohkanda, Ratna D. Bailey, Andrew D. Hamilton and Saïd M. Sebti2

Drug Discovery Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Biochemistry and Molecular Biology, University of South Florida, Tampa, Florida 33612 [J. S., M. A. B., R. D. B., S. M. S.], and Yale University, Department of Chemistry, New Haven, Connecticut 06511 [D. K., Y. Q., J. O., A. D. H.]

Ras malignant transformation requires posttranslational modification by farnesyltransferase (FTase). Here we report on the design and antitumor activity, in monotherapy as well as in combination therapy with cytotoxic agents, of a novel class of non-thiol-containing peptidomimetic inhibitors of FTase and the closely related family member geranylgeranyltransferase I (GGTase I). The non-thiol-containing FTI-2148 is highly selective for FTase (IC50, 1.4 nM) over GGTase I (IC50, 1700 nM), whereas GGTI-2154 is highly selective for GGTase I (21 nM) over FTase (IC50, 5600 nM). In whole cells, the corresponding methylester prodrug FTI-2153 is >3000-fold more potent at inhibiting H-Ras (IC50, 10 nM) than Rap1A processing, whereas GGTI-2166 is over 100-fold more selective at inhibiting Rap1A (IC50, 300 nM) over H-Ras processing. Furthermore, FTI-2153 was highly effective at suppressing oncogenic H-Ras constitutive activation of mitogen-activated protein kinase and human tumor growth in soft agar. FTI-2148 suppressed the growth of the human lung adenocarcinoma A-549 cells in nude mice by 33, 67, and 91% in a dose-dependent manner. Combination therapy of FTI-2148 with either cisplatin, gemcitabine, or Taxol resulted in a greater antitumor efficacy than monotherapy. GGTI-2154 in similar antitumor efficacy experiments is less potent than FTI-2148 and inhibits tumor growth by 9, 27, and 46%. Combination therapy of GGTI-2154 with cisplatin, gemcitabine, or Taxol is also more effective. Finally, FTI-2148 and GGTI-2154 are 30- and 33-fold more selective and 30- and 16-fold more potent in whole cells than our previously reported thiol-containing FTI-276 and GGTI-297, respectively. Thus, our results demonstrate that this highly potent and selective novel class of non-thiol-containing peptidomimetics inhibits human tumor growth in whole animals and that combination therapy with cytotoxic agents is more beneficial than monotherapy.




This article has been cited by other articles:


Home page
 BloodHome page
J. E. Karp, K. Flatten, E. J. Feldman, J. M. Greer, D. A. Loegering, R. M. Ricklis, L. E. Morris, E. Ritchie, B. D. Smith, V. Ironside, et al.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Blood, May 14, 2009; 113(20): 4841 - 4852.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Shah, B. S. Shin, J. Veith, K. Toth, R. J. Bernacki, and J. P. Balthasar
Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 580 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Lu, L. Chan, H. D.G. Fiji, R. Dahl, O. Kwon, and F. Tamanoi
In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I
Mol. Cancer Ther., May 1, 2009; 8(5): 1218 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Kazi, A. Carie, M. A. Blaskovich, C. Bucher, V. Thai, S. Moulder, H. Peng, D. Carrico, E. Pusateri, W. J. Pledger, et al.
Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy
Mol. Cell. Biol., April 15, 2009; 29(8): 2254 - 2263.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Zhou, C. C. Vos, A. Gjyrezi, M. Yoshida, F. R. Khuri, F. Tamanoi, and P. Giannakakou
The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner
J. Biol. Chem., April 10, 2009; 284(15): 9648 - 9655.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. J. Roberts, N. Mitin, P. J. Keller, E. J. Chenette, J. P. Madigan, R. O. Currin, A. D. Cox, O. Wilson, P. Kirschmeier, and C. J. Der
Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification
J. Biol. Chem., September 12, 2008; 283(37): 25150 - 25163.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. C. Falsetti, D.-a. Wang, H. Peng, D. Carrico, A. D. Cox, C. J. Der, A. D. Hamilton, and S. M. Sebti
Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth
Mol. Cell. Biol., November 15, 2007; 27(22): 8003 - 8014.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. An, B. Wei, B. Xia, J. M. McDaniel, T. Ju, R. D. Cummings, J. Braun, and L. Xia
Increased susceptibility to colitis and colorectal tumors in mice lacking core 3 derived O-glycans
J. Exp. Med., June 11, 2007; 204(6): 1417 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Schafer-Hales, J. Iaconelli, J. P. Snyder, A. Prussia, J. H. Nettles, A. El-Naggar, F. R. Khuri, P. Giannakakou, and A. I. Marcus
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function
Mol. Cancer Ther., April 1, 2007; 6(4): 1317 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Marcus, A. M. O'Brate, R. M. Buey, J. Zhou, S. Thomas, F. R. Khuri, J. M. Andreu, F. Diaz, and P. Giannakakou
Farnesyltransferase Inhibitors Reverse Taxane Resistance.
Cancer Res., September 1, 2006; 66(17): 8838 - 8846.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens
Development of Farnesyl Transferase Inhibitors: A Review
Oncologist, September 1, 2005; 10(8): 565 - 578.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Zhu, E. Gerbino, D. M. Beaupre, P. A. Mackley, C. Muro-Cacho, C. Beam, A. D. Hamilton, M. G. Lichtenheld, W. G. Kerr, W. Dalton, et al.
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells
Blood, June 15, 2005; 105(12): 4759 - 4766.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Marcus, J. Zhou, A. O'Brate, E. Hamel, J. Wong, M. Nivens, A. El-Naggar, T.-P. Yao, F. R. Khuri, and P. Giannakakou
The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Cancer Res., May 1, 2005; 65(9): 3883 - 3893.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-Q. Ding, B. Liu, J. L. Vaught, H. Yamauchi, and S. E. Lind
Anticancer Activity of the Antibiotic Clioquinol
Cancer Res., April 15, 2005; 65(8): 3389 - 3395.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. J. Chenette, A. Abo, and C. J. Der
Critical and Distinct Roles of Amino- and Carboxyl-terminal Sequences in Regulation of the Biological Activity of the Chp Atypical Rho GTPase
J. Biol. Chem., April 8, 2005; 280(14): 13784 - 13792.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. K. Dy, L. M. Bruzek, G. A. Croghan, S. Mandrekar, C. Erlichman, P. Peethambaram, H. C. Pitot, L. J. Hanson, J. M. Reid, A. Furth, et al.
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 1877 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Yang, H. C. Dan, M. Sun, Q. Liu, X.-m. Sun, R. I. Feldman, A. D. Hamilton, M. Polokoff, S. V. Nicosia, M. Herlyn, et al.
Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt
Cancer Res., July 1, 2004; 64(13): 4394 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Manne, F. Y. F. Lee, D. K. Bol, J. Gullo-Brown, C. R. Fairchild, L. J. Lombardo, R. A. Smykla, G. D. Vite, M.-L. D. Wen, C. Yu, et al.
Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models
Cancer Res., June 1, 2004; 64(11): 3974 - 3980.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, M. A. Blaskovich, R. K. Jain, F. Delarue, D. Paris, S. Brem, M. Wotoczek-Obadia, Q. Lin, D. Coppola, K. Choi, et al.
Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor
Cancer Res., May 15, 2004; 64(10): 3586 - 3592.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, J. Ohkanda, D. Coppola, H. Yin, M. Kothare, B. Busciglio, A. D. Hamilton, and S. M. Sebti
Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice
Cancer Res., December 15, 2003; 63(24): 8922 - 8929.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Buckner, K. Yokoyama, J. Lockman, K. Aikenhead, J. Ohkanda, M. Sadilek, S. Sebti, W. Van Voorhis, A. Hamilton, and M. H. Gelb
A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents
PNAS, December 9, 2003; 100(25): 15149 - 15153.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Sebti
Blocked Pathways: FTIs Shut Down Oncogene Signals
Oncologist, December 1, 2003; 8(90003): 30 - 38.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood, December 1, 2003; 102(12): 3880 - 3889.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. L. Joyce and A. D. Cox
Rac1 and Rac3 Are Targets for Geranylgeranyltransferase I Inhibitor-Mediated Inhibition of Signaling, Transformation, and Membrane Ruffling
Cancer Res., November 15, 2003; 63(22): 7959 - 7967.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, and E. J. Bernhard
Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations
Cancer Res., September 15, 2003; 63(18): 5656 - 5668.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, G. A. Croghan, C. Erlichman, R. S. Marks, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al.
A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2520 - 2526.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei, A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al.
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 1, 2003; 21(9): 1760 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Blaskovich, J. Sun, A. Cantor, J. Turkson, R. Jove, and S. M. Sebti
Discovery of JSI-124 (Cucurbitacin I), a Selective Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathway Inhibitor with Potent Antitumor Activity against Human and Murine Cancer Cells in Mice
Cancer Res., March 15, 2003; 63(6): 1270 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Lobell, D. Liu, C. A. Buser, J. P. Davide, E. DePuy, K. Hamilton, K. S. Koblan, Y. Lee, S. Mosser, S. L. Motzel, et al.
Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Mol. Cancer Ther., July 1, 2002; 1(9): 747 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Smith, M. G. Rowlands, E. Barrie, P. Workman, and L. R. Kelland
Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line
Clin. Cancer Res., June 1, 2002; 8(6): 2002 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Lobell, C. A. Omer, M. T. Abrams, H. G. Bhimnathwala, M. J. Brucker, C. A. Buser, J. P. Davide, S. J. deSolms, C. J. Dinsmore, M. S. Ellis-Hutchings, et al.
Evaluation of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models
Cancer Res., December 1, 2001; 61(24): 8758 - 8768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al.
Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer
Clin. Cancer Res., November 1, 2001; 7(11): 3544 - 3550.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. C. Rose, F. Y. F. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne
Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor
Cancer Res., October 1, 2001; 61(20): 7507 - 7517.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. D. Finder, J. L. Petrus, A. Hamilton, R. T. Villavicencio, B. R. Pitt, and S. M. Sebti
Signal transduction pathways of IL-1{beta}-mediated iNOS in pulmonary vascular smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, October 1, 2001; 281(4): L816 - L823.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Adjei
Blocking Oncogenic Ras Signaling for Cancer Therapy
J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann
Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines
Clin. Cancer Res., May 1, 2001; 7(5): 1438 - 1445.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
E. Cohen-Jonathan, S. M. Evans, C. J. Koch, R. J. Muschel, W. G. McKenna, J. Wu, and E. J. Bernhard
The Farnesyltransferase Inhibitor L744,832 Reduces Hypoxia in Tumors Expressing Activated H-ras
Cancer Res., March 1, 2001; 61(5): 2289 - 2293.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
A.-x. Liu, W. Du, J.-P. Liu, T. M. Jessell, and G. C. Prendergast
RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors
Mol. Cell. Biol., August 15, 2000; 20(16): 6105 - 6113.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
Z. Chen, J. Sun, A. Pradines, G. Favre, J. Adnane, and S. M. Sebti
Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice
J. Biol. Chem., June 9, 2000; 275(24): 17974 - 17978.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. C. Crespo, J. Ohkanda, T. J. Yen, A. D. Hamilton, and S. M. Sebti
The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer Cells
J. Biol. Chem., May 4, 2001; 276(19): 16161 - 16167.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. E. Huber, R. G. Robinson, A. Watkins, D. D. Nahas, M. T. Abrams, C. A. Buser, R. B. Lobell, D. Patrick, N. J. Anthony, C. J. Dinsmore, et al.
Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors
J. Biol. Chem., June 29, 2001; 276(27): 24457 - 24465.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.